Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(→Links) |
||
| (23 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases | [[File:Fibrates.svg.png|thumb|450px]] | ||
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. | |||
This fibrate reduces triglyceride and rises HDL-cholesterol<ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_ED007/_pdf How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?]</ref><ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_27425/_pdf Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.]</ref> | |||
<gallery> | <gallery> | ||
File:4528-62340-1-PB.jpg</gallery> | File:4528-62340-1-PB.jpg | ||
</gallery> | |||
<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599574/ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis]</ref> | <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599574/ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis]</ref> | ||
<ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | <ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | ||
< | |||
ursodeoxycholic acid and bezafibrate are under study in the treatment of [[biliar cirrhosis]] (See Figure in gallery). | |||
==Links== | |||
[http://www.scielo.br/pdf/ag/v51n3/0004-2803-ag-51-03-255.pdf Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?] | |||
==[[ATC]]== | |||
Lipid modifying agents | |||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | |||
|colspan=2| <center> | |||
: [[wikipedia:bezafibrate|bezafibrate]] | |||
<ref>http://www.whocc.no/atc_ddd_index/?code=C10AB02</ref></center> | |||
|} | |||
{{refs}} | |||
{{Wikidata|Q577387}} | |||
[[Category:Hepatotoxic substances]] | |||
Latest revision as of 15:21, 25 October 2024
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. This fibrate reduces triglyceride and rises HDL-cholesterol[1][2]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cirrhosis (See Figure in gallery).
Links
Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?
ATC
Lipid modifying agents
